The Function of B and T Lymphocyte Attenuator and Its Role in Transplantation

IF 2.2 4区 医学 Q4 IMMUNOLOGY
Apmis Pub Date : 2025-03-05 DOI:10.1111/apm.70012
Kai Ma, Heqiao Han, Yuchen Bao, Rongtao Chen, Yixuan Yang, Wenwei Shao
{"title":"The Function of B and T Lymphocyte Attenuator and Its Role in Transplantation","authors":"Kai Ma,&nbsp;Heqiao Han,&nbsp;Yuchen Bao,&nbsp;Rongtao Chen,&nbsp;Yixuan Yang,&nbsp;Wenwei Shao","doi":"10.1111/apm.70012","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Immune checkpoints are important molecules that regulate the immune response, preventing its overactivation from causing tissue damage and autoimmune diseases. B and T lymphocyte attenuator (BTLA) plays an important role in regulating the activation and suppression of the immune response as part of a bidirectional signaling complex. The BTLA and its ligand herpesvirus entry mediator (HVEM) interaction transmits inhibitory signals that suppress the biological activity of T cells, B cells, and DCs. In addition, BTLA–HVEM can affect the induction of Treg cells, further suggesting its important role in immune regulation. Organ transplantation is the ultimate treatment option for many patients with end-stage organ failure. Transplant rejection can cause damage to the transplanted organ, which seriously affects the prognosis of patients. Therefore, we would like to explore the potential application value of the BTLA–HVEM interaction to exert an immunosuppressive function and thus attenuate transplant rejection. We first reviewed the structure and function of BTLA and HVEM, then summarized their research progress in organ transplantation, and further explored the directions of potential future applications and the challenges of current BTLA–HVEM applications.</p>\n </div>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"133 3","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Apmis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apm.70012","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Immune checkpoints are important molecules that regulate the immune response, preventing its overactivation from causing tissue damage and autoimmune diseases. B and T lymphocyte attenuator (BTLA) plays an important role in regulating the activation and suppression of the immune response as part of a bidirectional signaling complex. The BTLA and its ligand herpesvirus entry mediator (HVEM) interaction transmits inhibitory signals that suppress the biological activity of T cells, B cells, and DCs. In addition, BTLA–HVEM can affect the induction of Treg cells, further suggesting its important role in immune regulation. Organ transplantation is the ultimate treatment option for many patients with end-stage organ failure. Transplant rejection can cause damage to the transplanted organ, which seriously affects the prognosis of patients. Therefore, we would like to explore the potential application value of the BTLA–HVEM interaction to exert an immunosuppressive function and thus attenuate transplant rejection. We first reviewed the structure and function of BTLA and HVEM, then summarized their research progress in organ transplantation, and further explored the directions of potential future applications and the challenges of current BTLA–HVEM applications.

B和T淋巴细胞衰减剂的功能及其在移植中的作用
免疫检查点是调节免疫反应的重要分子,防止其过度激活导致组织损伤和自身免疫性疾病。B和T淋巴细胞衰减因子(BTLA)作为双向信号复合物的一部分,在调节免疫反应的激活和抑制中起重要作用。BTLA及其配体疱疹病毒进入介质(HVEM)相互作用传递抑制信号,抑制T细胞、B细胞和dc的生物活性。此外,BTLA-HVEM可影响Treg细胞的诱导,进一步提示其在免疫调节中的重要作用。器官移植是许多终末期器官衰竭患者的最终治疗选择。移植排斥反应会对移植器官造成损害,严重影响患者的预后。因此,我们想探索BTLA-HVEM相互作用的潜在应用价值,以发挥免疫抑制功能,从而减轻移植排斥反应。我们首先综述了BTLA和HVEM的结构和功能,然后总结了它们在器官移植中的研究进展,并进一步探讨了BTLA - HVEM的潜在应用方向和当前应用面临的挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Apmis
Apmis 医学-病理学
CiteScore
5.20
自引率
0.00%
发文量
91
审稿时长
2 months
期刊介绍: APMIS, formerly Acta Pathologica, Microbiologica et Immunologica Scandinavica, has been published since 1924 by the Scandinavian Societies for Medical Microbiology and Pathology as a non-profit-making scientific journal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信